Characterization of the physicochemical properties of micelles composed of the novel platelet activating factor receptor antagonist, E5880 in an aqueous environment

Chemistry and Physics of Lipids

Volumn 124, Issue 2, 2003, Pages 103-109

  Asai, Yasuyuki ^a  

^a EISAI CO LTD   (Japan)

Author keywords

Micelle; Micropolarity; PAF antagonist; Structure; Surface tension

Indexed keywords

1 ETHYL 2 [N (2 METHOXYBENZOYL) N [2 METHOXY 3 [4 (OCTADECYLCARBAMOYLOXY)PIPERIDINOCARBONYLOXY]PROPOXYCARBONYL]AMINOMETHYL]PYRIDIN IUM CHLORIDE; 1 ETHYL 2 [N (2 METHOXYBENZOYL) N [2 METHOXY 3 [4 (OCTADECYLCARBAMOYLOXY)PIPERIDINOCARBONYLOXY]PROPOXYCARBONYL]AMINOMETHYL]PYRIDINIUM CHLORIDE; CETRIMONIUM CHLORIDE; HYDROCARBON; OCTADECYLTRIMETHYLAMMONIUM; SURFACTANT; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; CALCULATION; CONCENTRATION (PARAMETERS); MICELLE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; STRUCTURE ANALYSIS; SURFACE TENSION;

EID: 0038683233     PISSN: 00093084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-3084(03)00044-6     Document Type: Article

References (26)

1. Benveniste J., Henso P.M., Cochrance C.G. Leukicyte-dependent histamine release from rabbit platelets. The role of IgE, basophilis, and a platelet-activating factor. J. Exp. Med. 136:1972;1356-1377.
2. Bessin P., Bonnet J., Apffel D., Soulard C., Desgroux L., Pelas I., Benveniste J. Acute circulatory collapse caused by platelet-activating factor (PAF-acether). Eur. J. Pharmacol. 86:1983;403-413.
3. Blank M.L., Snyder F., Byers L.W., Brooks B., Muirhead E.E. Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. Biochem. Biophys. Res. Commun. 90:1979;1194-1200.
4. Dimorth K., Reichardt C. Uber pyridinumphenal-betaine und ibre verwendung zur charakteriserung der polarität von lösungsmitteln Liebig. Annals. 661:1963;1-37.
5. Greenspan P., Fowler S.D. Spectrofluorometric studies of the lipid probe, nile red. J. Lipid Res. 26:1985;780-789.
6. Gulari E., Gulari E., Tsunashima Y., Chu E. Photon correlation spectroscopy of particle distribution. J. Chem. Phys. 70:1979;3965-3972.
7. Hanahan D.J. Platelet activating factor: a biological active phosphoglycerid. Annu. Rev. Biochem. 55:1986;483-489.
8. Handa T., Saito H., Miyajima K. Phospholipid monolayers at the triolein-saline interface: production of microemulsion particles and conversion of monolayers to bilayers. Biochemistry. 29:1990;2884-2890.
9. Handa T., Saito H., Kakee A., Tanaka I., Miyajima K. Lateral interactions of pig apolipoprotein A-1 with egg yolk phosphatidylcholine and with cholesterol in mixed monolayers at the triolein-saline interface. Biochemistry. 31:1992;1415-1420.
10. Handley D.A., Van Valen R.G., Melden M.K., Flury S., Lee M.L. Inhibition and reversal of endotoxin-, aggregated IgG- and PAF-induced hypotension in the rat by SRI 63-072, a PAF receptor antagonist. Immunopharmacology. 12:1986;11-16.
11. Humphrey D.M., McManus L.M., Satouchi K., Hanahan D.J., Pinckard R.N. Vasoactive properties of acetyl glyceryl phosphorylcholine and analogues. Lab. Invest. 46:1982;422-427.
12. Imura Y., Terashita Z., Nishikawa K. Possible role platelet activating factor (PAF) in disseminated intravascular coagularion (DIC), evidenced by use of a PAF antagonist. Life Sci. 39:1986;111-117.
13. Israelachvili J.N., Mitchell D.J., Ninham B.W. Theory of selfassembly of lipid bilayers and vesicle. J. Chem. Soc. Faraday II. 470:1977;185-201.
14. Israelachvili J.N., Marceija S., Horn R.G. Physical principles of membrane organization. Q. Rev. Biophys. 13:1980;121-200.
15. Milliaris A., Binana-Limbelew W., Zana R. Fluorescence probing studies of surfactant aggregation in aqueous solutions of mixed ionic micelles. J. Colloid Interf. Sci. 110:1986;114-120.
16. Nagaoka J., Harada K., Kimura A., Kobayashi S., Murakami M., Yoshimura T., Yamada K., Asano O., Katayama K., Yamatsu I. Inhibitory effects of the novel platelet factor receptor antagonist, 1-ethyl-2-[N-(2-methyl)benzoyl-N-[(2R)-2-methyl-3-(4-octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl]aminomethyl-pyridinium chloride, in several experimentally induced shock models. Arzneimittel-Forschung Drug Res. 41:1991;719-724.
17. Oh-ishi S., Tamaki K., Hayashi M., Tsushima S., Nomura H. Suppression of phorbol myristate acetate-induced pleurisy by CV-3988. Chem. Pharm. Bull. 34:1986;4896-4898.
18. Rosen, M.J., 1978. Surfactants and Interfacial Phenomena. Wiley-Interscience.
19. Sackett D.L., Wolff J. Nile red, as a polarity sensitive fluorescent probe of hydrophobic protein surfaces. Anal. Biochem. 167:1987;228-234.
20. Saeki S., Masugi F., Ogihara T., Otsuka A., Kumahara Y., Watanabe K., Tamura K., Akashi A., Kumagai A. Effect of a-O-alkyl-2-acetyl-sn-glycero-3-phosphochoiline (platelet activating factor) on cardiac function in perfused guinea-pig heart. Life Sci. 37:1985;325-329.
21. Shaw J.O., Pinckard R.N., Ferrigmi K.S., McManus L.M., Hanahan D.J. Activation of human neutrophilis with 1-O-hexadecyl/octadecyl/-2-acetyl-sn-glycerol-3-phosphorylcholine (platelet activating factor). J. Immunol. 127:1981;1255-1259.
22. Takizawa H., Ishii A., Suzuki S., Shiga J., Miyamoto T. Bromchoconstriction induced by platelet-activating factor in the guinea pig and its inhibition by CV-3988, a PAF antagonist: serial changes in findings of lung histology and bronchalveolar lavage cell population. Int. Arch. Allergy Appl. Immunol. 86:1988;375-382.
23. Terashita Z., Tsushima S., Yoshida Y., Nomura H., Inada Y., Nishikawa K. CV-3988 - a specific antagonist of platelet activating factor (PAF). Life Sci. 32:1983;1975-1982.
24. Terashita Z., Imura Y., Takatani M., Tsushima S., Nishikawa N. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo. J. Pharmacol. Exp. Ther. 242:1987;263-268.
25. Tokumura A., Homma H., Hanahan D.J. Structural analogs of alkylacetylglycerophosphocholine inhibitory behavior on platelet activation. J. Biol. Chem. 260:1985;12710-12714.
26. Vargaftig B.B., Lefort J., Chigrard M., Benveniste J. Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostagrandin derivatives. Eur. J. Pharmacol. 65:1980;185-192.